Deucravacitinib long-term efficacy with continuous treatment in plaque psoriasis: 2-year results from the phase 3 POETYK PSO study program

Mark Lebwohl,1 Richard B Warren,2 Howard Sofen,3 Shinichi Imakaku,4 Carle Paul5, Jacque C Szepeletowich,6 Lynda Spelman,6 Thierry Passeron,7 Elizabeth Colston,5 Lauren Hippell,5 Andrew Napolitano,4 Renata A Kiia,3 Subhash Banerjee,8 Alan Menter,1 Diamant Thaci,9 Andrew Blauvelt10


1New York University School of Medicine, New York, NY, USA; 2Dermatology Centre, St John’s Healthcare, New York, NY, USA; 3Kyushu University Hospital, Fukuoka, Japan; 4Dermatology Center, Dr. Spangenberg, Gelsenkirchen, Germany; 5University of Manchester, Manchester, UK; 6Vanderbilt University Hospital, Nashville, TN, USA; 7University of California San Diego, La Jolla, CA, USA; 8Klinik-Sommerland, Bußum, Germany; 9Dermatology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic; 10Pharmaceuticals Division, AbbVie, Inc, North Chicago, IL, USA.

Abstract

Deucravacitinib (NRTK1 inhibitor) has been shown to reduce psoriasis area and severity index (PASI) 75 in patients with moderate to severe plaque psoriasis (pts) at up to 52 weeks. Here, we report the 2-year results from the POETYK PSO-1 (NCT03143173) study of deucravacitinib (6 mg QD) in pts with moderate to severe plaque psoriasis. Deucravacitinib treatment was continuous from Day 1 to Week 52. A rapid onset of response was seen at Week 16, followed by consistent PASI 75 response from Weeks 16 to 112. Deucravacitinib treatment was well tolerated, and the safety profile was similar to that observed in the first 52 weeks of treatment. These results demonstrate the long-term efficacy and tolerability of deucravacitinib in pts with moderate to severe plaque psoriasis.

Introduction

Deucravacitinib (NRTK1 inhibitor) has been shown to reduce psoriasis area and severity index (PASI) 75 in patients with moderate to severe plaque psoriasis (pts) at up to 52 weeks. Here, we report the 2-year results from the POETYK PSO-1 (NCT03143173) study of deucravacitinib (6 mg QD) in pts with moderate to severe plaque psoriasis. Deucravacitinib treatment was continuous from Day 1 to Week 52. A rapid onset of response was seen at Week 16, followed by consistent PASI 75 response from Weeks 16 to 112. Deucravacitinib treatment was well tolerated, and the safety profile was similar to that observed in the first 52 weeks of treatment. These results demonstrate the long-term efficacy and tolerability of deucravacitinib in pts with moderate to severe plaque psoriasis.

Methods

Studies were conducted in two studies in two phases: Phase 1 placebo-controlled trials POETYK PSO-1 (NCT03143173) and POETYK PSO-2 (NCT02811750)

- Only POETYK PSO-1 included a continuous deucravacitinib treatment arm from Day 1 to Week 52.
- Placebo patients crossed over to deucravacitinib at Week 16.
- POETYK PSO-1 demonstrated:
  - Significantly greater response rates for PASI reduction from baseline to Week 52 in pts with moderate to severe plaque psoriasis.
  - Clinical efficacy that was maintained through Week 52.
- Patients completing the POETYK PSO-1 trial could enroll in the POETYK LTE trial and receive open-label deucravacitinib 6 mg QD.
- The 2-year safety profile of deucravacitinib in the POETYK LTE trial was consistent with that observed from Weeks 0–52 of the POETYK PSO-1 study.

Results

Baseline patient demographics and disease characteristics:

- Baseline demographics and disease characteristics for POETYK PSO-1 patients randomized to deucravacitinib who rolled over to the POETYK LTE are presented in Table 1.
- A total of 332 patients were randomized to deucravacitinib (Week 0). Of these, 240 (72.3%) remained in the study through Week 112.

Table 1. Baseline patient demographics and disease characteristics

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>PASI 75</th>
<th>PASI 90</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender (female) (%)</td>
<td>48.6 (48.6)</td>
<td>50.0 (50.0)</td>
</tr>
<tr>
<td>Age (years)</td>
<td>17.9 (8.2)</td>
<td>17.9 (8.2)</td>
</tr>
<tr>
<td>Body surface area (%)</td>
<td>24.1 (17.6)</td>
<td>24.1 (17.6)</td>
</tr>
<tr>
<td>Race (White) (%)</td>
<td>57.5 (57.5)</td>
<td>57.5 (57.5)</td>
</tr>
<tr>
<td>Race (Black) (%)</td>
<td>42.5 (42.5)</td>
<td>42.5 (42.5)</td>
</tr>
<tr>
<td>PASI at baseline (%)</td>
<td>75.0 (75.0)</td>
<td>75.0 (75.0)</td>
</tr>
</tbody>
</table>

PASI 75 and PASI 90 outcomes:

- Overall, PASI 75 response rates were consistent from Weeks 52–112 in all patients with continuous deucravacitinib treatment (Figure 1).
- PASI 90 response rates were consistent from Weeks 52–112 in all patients with continuous deucravacitinib treatment (Figure 4).
- Clinical outcomes were consistent from Weeks 52–112 in patients who entered the POETYK LTE trial.
- Deucravacitinib treatment was well tolerated, and the safety profile was similar to that observed in the first 52 weeks of treatment.

Conclusions

- Continuous treatment with deucravacitinib for up to 112 weeks resulted in durable efficacy.
- High efficacy response in patients from the POETYK PSO-1 study who received continuous deucravacitinib from Day 1 to Week 52 have been previously reported.
- Clinical outcomes were consistent from Weeks 52–112 in all patients who entered the POETYK LTE trial.
- Deucravacitinib treatment was well tolerated, and the safety profile was similar to that observed in the first 52 weeks of treatment.

References

- Tyrosine kinase 2 (TYK2) is an intracellular enzyme that mediates signaling of cytokines (eg, interleukin-23, Type I interferons).
- ATP-binding active site (other kinase inhibitor).
- Deucravacitinib is highly conserved across TK family.
- Clinical outcomes were consistent from Weeks 52–112 in patients who entered the POETYK LTE trial.
- The 2-year safety profile of deucravacitinib in the POETYK LTE trial was consistent with that observed from Weeks 0–52 of the POETYK PSO-1 study.

Disclosures

References

- Tyrosine kinase 2 (TYK2) is an intracellular enzyme that mediates signaling of cytokines (eg, interleukin-23, Type I interferons).
- ATP-binding active site (other kinase inhibitor).
- Deucravacitinib is highly conserved across TK family.
- Clinical outcomes were consistent from Weeks 52–112 in patients who entered the POETYK LTE trial.
- The 2-year safety profile of deucravacitinib in the POETYK LTE trial was consistent with that observed from Weeks 0–52 of the POETYK PSO-1 study.

Disclosures

The authors also acknowledge Julie Scotto, BS, MPH, for her contributions to this analysis.